相关实验视频
Updated: Jan 16, 2026
10:04
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
12.1K
丹麦扩散型大B细胞淋巴瘤不同治疗线的总成本 - - 现实世界数据分析
Christian Graves Beck1, Martin Lucas Jørgensen2, Maya Friis Kjaergaard3
1Roche Pharmaceuticals A/S, Flaskehalsen 17, 4th Floor, Copenhagen, DK-1799, Denmark. Christian_graves.beck@roche.com.
概括
随着扩散型大B细胞淋巴瘤 (DLBCL) 的后期治疗线,医疗费用和疾病福利增加. 更有效的第一线治疗可能为患者和医疗保健系统提供经济优势.
科学领域:
- 在瘤学瘤学.
- 卫生经济学 卫生经济学
- 淋巴瘤研究 淋巴瘤研究
背景情况:
- 扩散性大B细胞淋巴瘤 (DLBCL) 是最常见的非霍奇金淋巴瘤.
- 虽然一线治疗提供了高的治愈率,但复发/耐药患者的结果很差.
- 最近批准新的DLBCL治疗需要了解治疗线路总成本.
研究的目的:
- 调查每一条DLBCL治疗线 (第一,第二,第三线和最佳支持性护理) 的总医疗费用.
- 估计患者的劳动力市场依附和疾病福利水平跨治疗线.
主要方法:
- 丹麦DLBCL患者 (2012-2021) 全国实况注册研究.
- 与国家注册表的数据链接,以计算每条处理线的总成本.
- 经调整为每月患者成本 (PPPM) 的成本进行分析.
主要成果:
- 包括4,159名DLBCL患者;随着后来的治疗线路,无进展时间减少.
- 每名患者的平均总医疗费用为51,660欧元 (1LoT),59,094欧元 (2LoT),35,808欧元 (3LoT+BSC).
- 每个PPPM的成本随着后续线路的增加而增加;劳动力市场的附属性较低,后续线路的疾病福利增加.
结论:
- 随着DLBCL治疗线路的晚期,总费用和疾病福利周增加.
- 更有效的第一线治疗对于患者的预后至关重要.
- 有效的第一线DLBCL疗法可以为医疗保健部门和社会带来经济效益.
更多相关视频
07:13Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model
Published on: April 18, 2025
490
12:16A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
Published on: October 16, 2018
15.4K
相关概念视频
01:21Cancer Survival Analysis
648
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
648
02:56Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K